Results 201 to 210 of about 46,900 (298)

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

In Vivo Inhibition of Dipeptidyl Peptidase 4 and Neprilysin Activity Enables Measurement of GLP-1 Secretion in Male Rats. [PDF]

J Endocr Soc
Galsgaard KD, Abba V, Kuhre RE, Holst JJ, Hartmann B.   +4 more
europepmc   +1 more source

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7196-7206, August 2026.
ABSTRACT Aims This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods Participants were randomised to receive the long‐acting
Tim Heise, Eric Zijlstra, Andrea Mari, William C. Roell, Kieren J. Mather, Axel Haupt, Panagiotis Flevaris, Ran Liao, Laiyi Chua, Charles Harris, Edward J. Pratt   +10 more
wiley   +1 more source

Phenotype-Specific Mortality Outcomes with Dipeptidyl Peptidase-4 Inhibitors in Heart Failure and Diabetes: Real-World Evidence from a Retrospective Single-Center Cohort Study. [PDF]

J Clin Med
Alfehaid L, Alamer A, Alhantush A, Yami MSA.   +3 more
europepmc   +1 more source

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6767-6775, August 2026.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim, Yun Kyung Cho, Mi‐Sook Kim, Joongyub Lee, Seonghae Kim, Bo Ram Yang   +5 more
wiley   +1 more source

Dipeptidyl Peptidase 4, a Novel Adipokine, Impairs Retinal Microcirculation in Patients With Type 2 Diabetes Mellitus. [PDF]

Invest Ophthalmol Vis Sci
Omae T, Ono S, Kamiya T, Otani S, Yokota H, Nagaoka T.   +5 more
europepmc   +1 more source

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6482-6508, August 2026.
ABSTRACT Aims We aimed to examine the association between GLP‐1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. Materials and Methods A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was conducted from database inception through December 11, 2025. Observational studies investigating
Timothy H. Chan, Leon E. Cosler, Michael R. Gionfriddo, Emily E. Leppien, Eleanor J. Sommers, Mia E. Lussier   +5 more
wiley   +1 more source

Increased Dipeptidyl Peptidase-4 Promotes Adipose Inflammation and Dysfunction in Mice Under Chronic Stress. [PDF]

FASEB J
Zhang M, Wang H, Li X, Shu S, Piao J, Yue X, Zhao S, Li M, Jin X, Nan Y, Cheng XW.   +10 more
europepmc   +1 more source